Piper Sandler initiated coverage of RxSight (RXST) with a Neutral rating and $18 price target The firm likes the company’s novel light ...

The RxSight ® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens ® (LAL™/LAL+ ®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first ...

CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL ... to highlight the benefits of RxSight’s adjustable IOL platform.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high estimate of $66.00, and a low estimate of $17.00. Experiencing a 18.74% decline, ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the sale of 73 Light Delivery Devices ...

RxSight faces revenue decline and rising competition in the IOL market. Click here to find out why I am neutral on RXST stock.

RxSight (NASDAQ:RXST), a maker of light-adjustable intraocular lenses, fell ~28% in the premarket on Thursday after the company slashed its full-year guidance and announced lower-than-expected ...

Q1 2025 Management View CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL) market, disruptions from sequential product launches by competitors ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the s ALISO VIEJO, Calif., April 02 ...

The LAL+ optical design further extends the depth of focus from the original design of the Light Adjustable Lens (RxSight) by adding a small continuous increase in central lens power relative to ...

STOP MISPLACING YOUR READERS. Losing your reading glasses is common, but with CliC they’ll always be around. The durable wrap around strap paired with the magnetic front connection keeps your ...